Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Michael GnantAmylou C DueckSophie FrantalMiguel MartinHal J BursteinRichard GreilPeter FoxAntonio C WolffArlene ChanEric P WinerGeorg PfeilerKathy D MillerMarco ColleoniJennifer M SugaGabor RubovszkyJudith M BlissIngrid A MayerChristian F SingerZbigniew NoweckiOlwen HahnJacqui ThomsonNorman WolmarkKepa AmillanoHope S RugoGuenther G StegerBlanca Hernando Fernández de AránguizTufia C HaddadAntonia PerellóMeritxell BelletHannes FohlerOtto Metzger FilhoAnita Jallitsch-HalperKadine SolomonCéline SchurmansKathy P TheallDongrui Ray LuKathleen TennerChristian FeslAngela M DeMicheleErica L Mayernull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor-positive breast cancer.